Revatio Pfizer Inc. - Treatment for Pulmonary Arterial Hypertension

Revatio contains sildenafil citrate, the active ingredient in the erectile dysfunction medication Viagra. Revatio is indicated for the treatment of pulmonary arterial hypertension (PAH), a rare, aggressive and life-shortening vascular disease.

Related Articles:

Pfizer Submits Regulatory Filings for Revatio as a Treatment for Pulmonary Arterial Hypertension - December 3, 2004

Latest FDA Drug Approvals...

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals